nafamostat has been researched along with Triple Negative Breast Neoplasms in 2 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nafamostat mesylate (NM) is a synthetic compound that inhibits various serine proteases and has been used as a therapeutic agent for the treatment of TNBC." | 1.91 | Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy. ( Chen, D; Huang, M; Jiang, L; Li, H; Xu, P; Yu, S; Yuan, C; Zhou, Y, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, Y | 3 |
| Yu, S | 3 |
| Chen, D | 3 |
| Li, H | 3 |
| Xu, P | 3 |
| Yuan, C | 3 |
| Jiang, L | 3 |
| Huang, M | 3 |
| Mander, S | 1 |
| You, DJ | 1 |
| Park, S | 1 |
| Kim, DH | 1 |
| Yong, HJ | 1 |
| Kim, DS | 1 |
| Ahn, C | 1 |
| Kim, YH | 1 |
| Seong, JY | 1 |
| Hwang, JI | 1 |
2 other studies available for nafamostat and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.
Topics: Animals; Humans; Mice; Receptors, Urokinase Plasminogen Activator; Serum Albumin, Human; Treatment O | 2023 |
Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.
Topics: Animals; Humans; Mice; Receptors, Urokinase Plasminogen Activator; Serum Albumin, Human; Treatment O | 2023 |
Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.
Topics: Animals; Humans; Mice; Receptors, Urokinase Plasminogen Activator; Serum Albumin, Human; Treatment O | 2023 |
Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.
Topics: Animals; Humans; Mice; Receptors, Urokinase Plasminogen Activator; Serum Albumin, Human; Treatment O | 2023 |
Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Benzamidines; Cell Movement; Female; Guanidines; Humans; MCF-7 Cells | 2018 |